A new study suggests that pretreatment with cyclophosphamide can enhance treatment benefit in otherwise refractory patients with myasthenia gravis. Eight patients with myasthenia gravis that was unresponsive to standard therapy received intravenous cyclophosphamide for 6 weeks. Six of the eight patients responded well to standard immunotherapies after cyclophosphamide induction, and four of them remained in remission for over 2 years.